A drug called OBI-3424 has been designated an Orphan Drug by the U.S. Food and Drug Administration (FDA) to treat acute lymphoblastic leukaemia, based predominantly on research carried out by our Leukaemia Biology Program.
September marks Children’s Cancer Awareness Month, a time to bring awareness of the devastating effects of childhood cancer and raise vital funds for research into finding a cure. To commemorate, Children’s Cancer Institute has engaged in a variety of awareness and fundraising activities throughout the month.
Research published this week shows that gold-coated nanoparticles can be used to detect tiny amounts of cancer-related molecules in blood.
It’s six months since the Zero Childhood Cancer personalised medicine national clinical trial began. We'd like to share some of our progress with you.
Ground-breaking virtual reality (VR) technology is allowing multiple scientists to see inside a human cell at the same time.
If doctors can reliably tell which children are most likely to get their leukaemia back, they can offer more intensive treatment options to prevent it.
This week our higher degree students presented their research at the 5th annual UNSW Paediatric Research Week.
Brain cancers are the leading disease-related cause of death in Australian children. In this article, first published in The Conversation, A/Prof David Ziegler explains what we can learn from improving childhood leukaemia survival.
WA children with the most aggressive cancers will benefit from an Australian-first personalised medicine clinical trial.
We presented exciting results from preclinical drug testing at a cancer conference this week in the US.